Description

In this episode, Dr. Stefan Zeuzem discusses results from key viral hepatitis studies reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver, including important findings from the following reports:

• Update on global progress toward HCV elimination goals
• SToP-C: HCV treatment-as-prevention in Australian prisons
• SHARED cohort: correlates of treatment failure with GLE/PIB or SOF/VEL/VOX
• Trio Health: retreating HCV with GLE/PIB or SOF/VEL/VOX after DAA failure
• Stop-NUC: discontinuation of long-term nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic HBV infection
• High-dose bulevirtide for chronic HBV/HDV coinfection
• Summary of select agents under early-phase investigation for HBV treatment

Presenter:

Stefan Zeuzem, MD
Professor of Medicine  
Chief, Department of Medicine I  
JW Goethe University Hospital  
Frankfurt, Germany

Content based on a CME program supported by an independent educational grant from Gilead Sciences.

Link to full program:
https://bit.ly/33nkRUI

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.